Mpox media information
![Mpox media information Mpox media information](/media/356118/jynneos01.jpg)
PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.
April 2, 2024
Bavarian Nordic announced the commercial launch of JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) in the U.S.
JYNNEOS is the only FDA-approved mpox vaccine and was made available for individuals at risk during the 2022-2023 mpox outbreak by the U.S. government.
JYNNEOS is now recommended for routine use in individuals 18 years and older with certain risk factors, and is now available nationwide for wholesaler and distribution partners to make it available for individuals at risk at local pharmacies and physician offices in addition to public health clinics.
Read more in the press release below.